Security Snapshot

SUPERNUS PHARMACEUTICALS, INC. - Common Stock (SUPN) Institutional Ownership

CUSIP: 868459108

13F Institutional Holders and Ownership History from Q1 2014 to Q1 2026

Latest Period

Q1 2026

Institutions Reporting

325

Shares (Excl. Options)

58,220,249

Price

$51.69

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Type / Class
Equity / Common Stock
Symbol
SUPN on Nasdaq
Shares outstanding
57,671,650
Price per share
$51.53
All holders as of 31 Mar 2026
Q1 2026
Total 13F shares
58,220,249
Total reported value
$3,007,190,873
% of total 13F portfolios
0%
Share change
+1,099,153
Value change
+$59,260,749
Number of holders
325
Price from insider filings
$51.53
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Key facts

  • SUPN - SUPERNUS PHARMACEUTICALS, INC. - Common Stock is tracked under CUSIP 868459108.
  • 325 institutions reported positions in Q1 2026.
  • 6 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 332 to 325 between Q4 2025 and Q1 2026.
  • Reported value moved from $2,839,113,187 to $3,007,190,873.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 325 institutions filings for Q1 2026.

Open SEC Evidence

Security key

868459108

Latest holder period

Q1 2026

13F holders

325

13D/G owners

6

CIK / CUSIP context first

Open Q1 2026 holders SUPN full holder history SUPERNUS PHARMACEUTICALS, INC. SEC filings SUPERNUS PHARMACEUTICALS, INC. company facts SUPERNUS PHARMACEUTICALS, INC. insider transactions

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
6
Security
SUPN
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 15% $266,321,277 8,197,023 BlackRock, Inc. 31 Mar 2025
MILLENNIUM MANAGEMENT LLC 5.7% +8% $161,652,355 +$12,092,936 3,281,615 +8.1% Millennium Management LLC 11 Feb 2026
VANGUARD PORTFOLIO MANAGEMENT LLC 5.7% $168,680,442 3,263,309 Vanguard Portfolio Management 31 Mar 2026
VANGUARD CAPITAL MANAGEMENT LLC 5% $149,946,694 2,900,884 Vanguard Capital Management 31 Mar 2026
ARMISTICE CAPITAL, LLC 4.8% -4.8% $136,154,640 -$3,546,720 2,764,000 -2.5% Armistice Capital, LLC 31 Dec 2025
DIMENSIONAL FUND ADVISORS LP 4.7% $134,803,348 2,712,341 Dimensional Fund Advisors LP 31 Dec 2025

As of 31 Mar 2026, 325 institutional investors reported holding 58,220,249 shares of SUPERNUS PHARMACEUTICALS, INC. - Common Stock (SUPN). This represents 101% of the company’s total 57,671,650 outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
76%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 15% 8,797,254 +0.7% 0.01% $454,730,061
MILLENNIUM MANAGEMENT LLC 5.7% 3,315,973 +26% 0.13% $171,402,644
VANGUARD PORTFOLIO MANAGEMENT LLC 5.6% 3,238,693 0% 0.01% $167,408,041
VANGUARD CAPITAL MANAGEMENT LLC 4.3% 2,467,215 0% 0% $127,530,343
DIMENSIONAL FUND ADVISORS LP 4% 2,307,030 -15% 0.02% $119,239,273
STATE STREET CORP 4% 2,288,127 +3.1% 0% $118,273,285
NOMURA ASSET MANAGEMENT INTERNATIONAL INC. 3.5% 2,037,202 -12% 0.18% $105,303,000
ARMISTICE CAPITAL, LLC 3.3% 1,895,347 -31% 3.2% $97,970,486
RENAISSANCE TECHNOLOGIES LLC 3% 1,705,222 -1.6% 0.14% $88,142,925
GEODE CAPITAL MANAGEMENT, LLC 2.8% 1,623,514 +10% 0.01% $83,933,938
CITADEL ADVISORS LLC 2.6% 1,493,446 +230% 0.05% $77,196,223
LOOMIS SAYLES & CO L P 2.5% 1,425,779 -1.6% 0.1% $73,698,522
Stephens Investment Management Group LLC 2.3% 1,351,331 -3.9% 0.96% $69,850,299
Point72 Asset Management, L.P. 2.3% 1,318,555 -42% 0.12% $68,156,108
GW&K Investment Management, LLC 1.8% 1,055,184 -2.4% 0.48% $54,542,000
Sofinnova Investments, Inc. 1.7% 954,309 +73% 2.5% $49,328,232
MORGAN STANLEY 1.6% 913,893 -15% 0% $47,239,157
GOLDMAN SACHS GROUP INC 1.5% 856,487 +30% 0.01% $44,271,813
BANK OF AMERICA CORP /DE/ 1.2% 714,226 +37% 0% $36,918,329
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 1.2% 705,976 +0.33% 0.01% $36,491,899
NORTHERN TRUST CORP 1.2% 699,456 +4.3% 0% $36,154,881
ASHFORD CAPITAL MANAGEMENT INC 1.1% 645,381 +5.4% 4.1% $33,359,744
Freestone Grove Partners LP 1.1% 641,319 +227% 0.24% $33,149,779
D. E. Shaw & Co., Inc. 1.1% 622,450 -12% 0.03% $32,174,441
Assenagon Asset Management S.A. 0.92% 530,618 0.04% $27,427,644

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
49
Latest
Q1 2026
Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 58,220,249 $3,007,190,873 +$59,260,749 $51.69 325
2025 Q4 57,114,664 $2,839,113,187 -$131,385,144 $49.70 332
2025 Q3 57,682,442 $2,756,480,706 -$55,160,794 $47.79 306
2025 Q2 59,473,450 $1,874,807,260 +$9,630,477 $31.52 292
2025 Q1 59,101,687 $1,935,404,930 -$15,482,554 $32.75 289
2024 Q4 59,487,720 $2,151,322,834 -$22,020,752 $36.16 289
2024 Q3 59,870,229 $1,866,730,333 +$55,809,134 $31.18 269
2024 Q2 58,408,045 $1,562,624,874 +$31,544,259 $26.75 241
2024 Q1 56,687,119 $1,933,242,340 -$13,205,166 $34.11 246
2023 Q4 57,120,264 $1,653,064,952 +$17,403,885 $28.94 244
2023 Q3 56,959,606 $1,570,365,603 -$13,068,601 $27.57 235
2023 Q2 57,192,976 $1,719,305,714 +$49,379,666 $30.06 244
2023 Q1 55,275,699 $2,002,621,195 -$15,673,429 $36.23 254
2022 Q4 55,885,167 $1,993,935,462 +$8,207,715 $35.67 259
2022 Q3 55,685,346 $1,884,907,309 +$24,605,478 $33.85 236
2022 Q2 54,730,295 $1,582,868,015 +$42,197,813 $28.92 214
2022 Q1 53,502,805 $1,728,247,579 -$41,233,819 $32.32 220
2021 Q4 55,217,286 $1,609,193,475 +$18,456,601 $29.16 226
2021 Q3 54,377,202 $1,451,011,413 +$3,672,754 $26.67 217
2021 Q2 54,148,773 $1,667,192,127 +$29,163,166 $30.79 222
2021 Q1 53,335,145 $1,397,017,874 +$13,336,729 $26.18 217
2020 Q4 52,923,548 $1,331,865,761 +$29,078,257 $25.16 219
2020 Q3 51,463,966 $1,072,432,929 +$15,343,379 $20.84 204
2020 Q2 50,545,295 $1,200,362,920 +$48,582,918 $23.75 213
2020 Q1 48,465,165 $871,862,986 -$52,617,228 $17.99 199
2019 Q4 51,308,069 $1,216,964,651 +$7,789,909 $23.72 230
2019 Q3 50,639,622 $1,391,452,892 -$78,862,126 $27.48 236
2019 Q2 52,880,406 $1,749,297,467 -$144,709 $33.09 267
2019 Q1 53,019,825 $1,857,817,308 +$46,099,024 $35.04 281
2018 Q4 51,698,203 $1,717,121,218 -$19,969,207 $33.22 265
2018 Q3 51,704,247 $2,602,686,438 -$125,772,976 $50.35 282
2018 Q2 53,624,393 $3,206,365,565 +$162,150,149 $59.85 317
2018 Q1 51,276,608 $2,344,528,500 +$80,955,651 $45.80 308
2017 Q4 49,688,862 $1,981,355,785 -$48,904,009 $39.85 294
2017 Q3 50,838,757 $2,034,247,120 +$109,501,908 $40.00 273
2017 Q2 47,330,397 $2,039,414,220 +$105,035,296 $43.10 262
2017 Q1 46,114,534 $1,443,390,915 +$218,131,286 $31.30 244
2016 Q4 45,333,093 $1,144,464,006 -$18,622,502 $25.25 229
2016 Q3 46,037,041 $1,135,870,536 -$9,181,554 $24.73 218
2016 Q2 46,516,239 $947,641,508 +$64,706,175 $20.37 210
2016 Q1 44,933,850 $685,195,121 +$7,308,210 $15.25 209
2015 Q4 44,768,531 $602,208,907 -$42,998,885 $13.44 205
2015 Q3 46,847,791 $657,293,219 +$62,276,957 $14.03 179
2015 Q2 42,547,309 $722,438,662 +$78,289,744 $16.98 163
2015 Q1 40,418,381 $488,565,846 +$44,904,974 $12.09 116
2014 Q4 37,070,882 $307,725,828 +$10,426,090 $8.30 105
2014 Q3 35,649,698 $309,782,879 -$17,884,207 $8.69 93
2014 Q2 37,124,609 $405,366,758 +$42,350,563 $10.95 87
2014 Q1 33,409,780 $298,611,368 +$21,545,722 $8.94 83
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .